Año |
Título |
Autores |
|
2015
|
Esx vivo host and parasite response to antileishmanial drugs and immunomodulators
|
Gonzalez-Fajardo L; Fernández O; McMahon-Pratt D; Gore Saravia N. |
|
2013
|
Estrategias para la implementación y reporte de los puntos de corte CLSI vigentes y pruebas fenotípicas confirmatorias para BLEE y carbapenemasas en bacilos Gram negativos en laboratorios clínicos de Colombia
|
Esparza G; Ariza B; Bedoya AM; Bustos AM; Catañeda-Ramírez CR; De la Cedena E; González de Arias MN; Guerrero L; Leal AL; Marín A; Meléndez MP; Rico CL; Villegas MV and Comité de Resistencia Bacteriana e IAAS ACIN |
|
2016
|
Epidemiology of candida isolates from Intensive Care Units in Colombia from 2010 to 2013
|
Motoa G; Muñoz JS; Oñate J; Pallares CJ; Hernandez C; Villegas MV |
|
2017
|
Epidemiology of candida isolates from Intensive Care Units in Colombia from 2010 to 2013
|
Motoa G; Muñoz JS; Oñate J; Pallares CJ; Hernandez C; Villegas MV. |
|
2012
|
Environmental factors associated with American cutaneous leishmaniasis in a new Andean focus in Colombia.
|
Ocampo CB; Ferro MC; Cadena H; Gongora R; Pérez M; Valderrama-Ardila CH, Quinnell RJ, Alexander N. |
|
2014
|
Emergence of resistance to miltefosine following treatment of dermal leishmaniasis.
|
Obonaga R; Fernández O; Valderrama L; Rubiano LC; Castro MM; Barrera MC; Gómez MA; Saravia NG. |
|
2014
|
Emergence of OXA-72-producing Acinetobacter pittii clinical isolates.
|
Bonnina RA; Docobo-Péreza F; Poirela L; Villegas MV |
|
2013
|
Emergence of Klebsiella pneumoniae Co-harboring KPC and VIM Carbapenemases in Colombia
|
Rojas LJ; Mojica MF; Blanco VM; Correa A; Montealegre MC; De La Cadena E; Maya JJ; Camargo RD; Quinn JP; Villegas MV |
|
2019
|
Eligibility for local therapies in adolescents and adults with cutaneous leishmaniasis from southwestern Colombia: a cross-sectional study
|
Uribe-Restrepo A; Prieto MD; Cossio A; Mayur D; Castro MM |
|
2015
|
DNA-containing immunocomplexes promote inflammasome assembly and release of pyrogenic cytokines by CD14+ CD16+ CD64high CD32low inflammatory monocytes from malaria patients
|
Hirakoa IC; Gallego-Marín C; Ataide MA; Andrade WA; Gravina H; Rocha BC; de Oliveira RB; Pereira DB; Vinetz J; Diamond B; Ramb S; Golenboch DT; Gazzinelli RT. |
|